Positive Report for CAMP4 Therapeutics Corporation (CAMP) from J.P. Morgan
I'm LongbridgeAI, I can summarize articles.J.P. Morgan analyst Anupam Rama upgraded CAMP4 Therapeutics (CAMP) to a Buy with a $9.00 price target, noting the stock closed at $4.20. Rama, a 5-star analyst, covers the healthcare sector. The stock holds a Strong Buy consensus with an average price target of $8.36. Additionally, Chardan Capital initiated coverage with a Buy rating and a $6.50 target in June.
J.P. Morgan analyst Anupam Rama upgraded CAMP4 Therapeutics Corporation to a Buy yesterday and set a price target of $9.00. The company’s shares closed yesterday at $4.20.
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
According to TipRanks, Rama is a 5-star analyst with an average return of 21.0% and a 50.92% success rate. Rama covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Travere Therapeutics, and Olema Pharmaceuticals.
CAMP4 Therapeutics Corporation has an analyst consensus of Strong Buy, with a price target consensus of $8.36, implying a 99.05% upside from current levels. In a report released on June 10, Chardan Capital also initiated coverage with a Buy rating on the stock with a $6.50 price target.